Lam Hung-Ming, Vessella Robert L, Morrissey Colm
Drug Discov Today Technol. 2014 Mar;11:41-7. doi: 10.1016/j.ddtec.2014.02.002.
Disseminated tumor cells (DTC) leave the primary tumor and reside in distant sites (e.g. bone) early in prostate cancer. Patients may harbor dormant DTC which develop into clinically overt metastasis years after radical prostatectomy. We will describe recent evidence suggesting high p38/ERK ratio, bone morphogenetic proteins, and tumor growth factor-beta 2 promote dormancy in solid tumors. Furthermore, we will discuss the possible regulation of dormancy by hematopoietic stem cell and vascular niches, and describe novel models recapitulating bone marrow metastatic latency and out- growth, 3D microvascular networks, and 3D biomatrix supportive niches in the studies of tumor cell dormancy.
播散肿瘤细胞(DTC)在前列腺癌早期离开原发肿瘤并驻留在远处部位(如骨骼)。患者可能携带休眠的DTC,在根治性前列腺切除术后数年发展为临床明显的转移灶。我们将描述最近的证据,表明高p38/ERK比值、骨形态发生蛋白和肿瘤生长因子-β2促进实体瘤中的休眠。此外,我们将讨论造血干细胞和血管龛对休眠的可能调节,并描述在肿瘤细胞休眠研究中重现骨髓转移潜伏期和生长、三维微血管网络以及三维生物基质支持龛的新模型。